PDE6A Gene Therapy for Retinitis Pigmentosa

• Status: Recruiting
• Trial end date: 2025-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The PDE6A gene encodes a subunit of the rod phosphodiesterase. The loss of this enzyme function leads to a chronically elevated cGMP level which causes an increased calcium inflow into the cell and thereby the hyperactivation of cell death pathways. The goal of the PIGMENT study is to develop, produce and investigate a recombinant adeno-associated viral (AAV) gene transfer vector for the curative therapy of PDE6A-linked retinitis pigmentosa in patients, in order to counteract their disease progression and to stop further impairment of visual function. The vector is given with a single subretinal injection.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: STZ eyetrial

Criteria

Inclusion Criteria:

• clinical diagnosis of retinitis pigmentosa

• confirmed mutation in PDE6A gene

• ≥ 18 years of age

• visual acuity ≥ 20/400

• no infection with Human Immundeficiency Virus (HIV)

• negative pregnancy test in women with childbearing potential (a woman who is two years post-menopausal or surgically sterile is not considered to be of childbearing potential)

• Male patients must agree to use condoms during the first 6 months post treatment.

• Female patients of childbearing potential must agree to use an effective method of birth control during the first 6 months post treatment.

• ability to understand and willingness to consent to study protocol

Exclusion Criteria:

Ocular (study eye & fellow eye)

• additional interfering ocular conditions with impact on study results (e.g. ocular opacity and advanced cataract, uveitis, amblyopia)

• recent (6 months) ocular surgery, intravitreal or subretinal implantation of a medical device

• disease causing mutations in another known retinitis pigmentosa gene

• ocular infection with herpes simplex virus in medical history

• history of ocular malignancies

• disorders of the internal retina (e.g. retinal detachment in the patients history)

• glaucoma defined as damage of the optic nerve

• vascular retinal occlusion

• diabetic patients suffering from retinopathy and/or macula edema

• any other retinopathy due to other diseases e.g. (but not limited to) arterial hypertension, trauma or acquired inflammatory diseases (uveitis serology), contraindication to pharmacological mydriasis (e.g. history of angle block glaucoma)

• absence of visual function on the contralateral eye Systemic

• systemic conditions (e.g. coronary heart disease, autoimmune disorders) which may affect study participation or outcome measures

• History of poorly controlled Diabetes Mellitus type 1 or type 2

• systemic illness or medically relevant abnormal laboratory values in blood analysis including renal and hepatic functions at inclusion

• patients treated with oral corticoids within 14 days prior inclusion

• current or recent participation in other study/or administration of biologic agent within the last three months

• known sensitivity to any compound used in the study

• contraindications to systemic immunosuppression

• contraindications in view of the planned surgery (e.g. but not limited to anaemia Hb<10g/dl, coagulopathy with PT/PTT >1,5 fold upper limit, hypertension with values above 180 mmHg systolic and 110 mmHg diastolic) including intolerance and contraindications to general anaesthesia

• intolerance to contrast agents used for diagnostic methods like angiography with fluoresceine or indocyanine green (e.g. but not limited to hyperthyroidism, hepatic insufficiency)

• subject/partner of childbearing potential unwilling to use adequate contraception for four months

• nursing or pregnant women

• any other cause that, in the investigator's opinion, renders potential subjects not suitable for the study